

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**  
**金斯瑞生物科技股份有限公司\***  
(Incorporated in the Cayman Islands with limited liability)  
(Stock Code: 1548)

## **CLARIFICATION ANNOUNCEMENT**

This announcement is made by the board of directors (the “**Board**”) of Genscript Biotech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)(the “**SFO**”).

Reference is made to the inside information announcements of the Company dated 22 December 2017 (the “**2017 Announcement**”) and 17 December 2018 (the “**2018 Announcement**”). As disclosed in the 2017 Announcement, (i) Legend Biotech USA Inc., a non-wholly-owned subsidiary of the Company (“**Legend U.S.**”), (ii) Legend Biotech Ireland Limited, a non-wholly-owned subsidiary of the Company (“**Legend Ireland**”, together with Legend U.S., “**Legend**”), and (iii) Janssen Biotech, Inc. (“**Janssen**”) entered into a collaboration and license agreement (the “**Agreement**”) on 22 December 2017. According to the Agreement, on top of the upfront payment of US\$350,000,000, Janssen shall make milestone payments (subject to achievement of the relevant milestone events) upon the first occurrence of various milestone events. Also, as disclosed in the 2018 Announcement on achieving major milestone in the collaboration with Janssen, according to the terms and conditions of the Agreement, the first milestone relating to the clinical trial in the US has been achieved and Legend is entitled to a milestone payment in the amount of US\$25,000,000 payable by Janssen.

The Board noted that on 16 April 2019, Dr. Xiaohu Fan (“**Dr. Fan**”), the Chief Scientist of Legend Biotech Corporation, a subsidiary of the Company, made a presentation (the “**Presentation**”) at a press conference organised by National Research Center for Translational Medicine of Shanghai, Jiangning District Government, People’s Hospital of Jiangsu Province and our Company. In the Presentation, Dr. Fan made some inaccurate statements in relation to the milestone payments of the Agreement (the “**Statements**”).

In response to the Statements, the Board would like to clarify that such Statements were inaccurate. The Board would like to emphasize that Dr. Fan had no involvement in the negotiation on the commercial and financial terms of the Agreement, and he was not aware of the final financial figures of the subsequent milestone payments as set out in the Agreement. Dr. Fan made the Statements based on his personal opinion and personal expectation on the amount of the expected milestone payments, and should not be considered as any indication of the future profitability of the Company.

The Board has reminded Dr. Fan and the management team of the Group of the importance of disclosure of information strictly in accordance with the line of any public announcement made by the Company, as well as the undesirable consequences of failing to act accordingly. The Company has also adopted corrective measures to prevent such matters from recurring in the future, such as provision of trainings regarding the proper disclosure of information to the public and signing of the warrant letters by the relevant employees.

**Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise in caution when they deal or contemplate dealing in the securities of the Company.**

By order of the Board  
**Genscript Biotech Corporation**  
**Zhang Fangliang**  
*Chairman and Chief Executive Officer*

Hong Kong, 23 July 2019

*As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Mr. Pan Jiuan.*

\* *For identification purposes only*